02:00 Wed 14 Jul 2021
ReNeuron Group plc - Board Change
ReNeuron Group plc
("ReNeuron" or the "Company")
Board Change
ReNeuron Group plc (AIM: RENE), a
Disclosures in accordance with the AIM Rules
Current Partnerships and Directorships:
Axicos AG
Assura Holding SA
Assura SA
Assura-Basis SA
Figeas SA
ABC Invest & Medical GmbH
Dybly AG
Ava AG
Prior Partnerships & Directorships:
Keires AG
In 2009,
In 1997,
There are no further disclosures required in accordance with AIM Rule 17 and Schedule Two paragraph (g) of the AIM Rules for Companies.
ENDS
Contacts:
ReNeuron |
|
|
Via Walbrook PR |
|
|
Stifel Nicolaus Europe Limited (NOMAD and Joint Broker) |
+44 (0)20 7710 7600
|
|
|
Allenby Capital Limited (Joint Broker) |
+44 (0)20 3328 5656 |
|
|
|
|
|
|
Walbrook PR (Media & Investor Relations) |
+44 (0)20 7933 8780 or reneuron@walbrookpr.com |
|
+44 (0)7980 541 893 / +44 (0)7407 804 654 |
About ReNeuron
ReNeuron is a global leader in cell-based therapeutics, harnessing its unique stem cell technologies to develop 'off the shelf' stem cell treatments for disease with significant unmet needs. The Company's lead cell therapy candidate is in clinical development for the blindness-causing disease, retinitis pigmentosa.
ReNeuron is also advancing its proprietary exosome technology platform as a potential delivery system for drugs that treat diseases of the central nervous system and other disorders. The Company also has the ability through its conditionally immortalised induced pluripotent stem cell (iPSC) platform to make allogeneic tissue cells of choice; in-house programmes are currently focused on treatments for blood cancers and diabetes.
ReNeuron's shares are traded on the London AIM market under the symbol RENE.L. For further information visit www.reneuron.com
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of...
FOR OUR FULL DISCLAIMER CLICK HERE